Clinical trials: Primary
Subclinical hypothyroïdism, Non-Alcoholic Fatty Liver Disease
Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues
additive efficacy of physical activity program in hypthyroidism in elder females with glaucoma and fatty liver issues was not investigated
- Conditions
- Subclinical hypothyroïdism, Non-Alcoholic Fatty Liver Disease, Primary Open Angle Glaucoma
- Trial name
- NCT07599241
- Testing
- physical activity, usual care
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Primary Hepatocellular Carcinoma
Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
Title: Single-center, open clinical study on the efficacy and safety of c-Met/PD-L1 T cell injection in the treatment of primary hepatocellular carcinoma Stage: Phase I clinical trial Purpose: To evaluate the efficacy and safety…
- Trial name
- NCT03672305
- Testing
- c-Met/PD-L1 CAR-T cell injection
- Volunteers
- 50 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Breast Cancer
Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
This is a Phase 1, open-label, dose escalation study in women with primary, non-recurrent breast cancer undergoing surgery. AVB-620 will be administered prior to surgery.
- Trial name
- NCT02391194
- Testing
- AVB-620
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Avelas Biosciences, Inc.
Hereditary Angioedema
A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema
The main aim of the study is to check for side effects from icatibant in children and teenagers with hereditary angioedema (HAE).
- Trial name
- NCT04654351
- Testing
- TAK-667
- Where
- 3 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Takeda
Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
This phase I trial studies the side effects and best dose of vorinostat when given together with pembrolizumab in treating patients with diffuse large B-cell lymphoma, follicular lymphoma, or Hodgkin lymphoma that has come back…
- Conditions
- Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL, Recurrent Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03150329
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- City of Hope Medical Center
Insomnia, Primary
Study of Low Field Magnetic Stimulation (LFMS) on Measures of Sleep
Participants will be recruited and screened through ongoing studies in the sleep and anxiety disorders clinic. Participants with insomnia will be consented to complete several questionnaires, undergo a brief physical exam…
- Trial name
- NCT03050372
- Testing
- LFMS - Active
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Dentin Caries
Comparison Of Clinical And Radiological Success Of Pulpotomy Treatments Performed With Proroot MTA, NeoPUTTY MTA, TheraCal PT In Primary Teeth
The goal of this randomized clinical trial is to compare clinical and radiological success rates of NeoPutty MTA, ProRoot MTA and TheraCal PT pulpotomy in 4-10 years old healthy pediatric patients.
- Trial name
- NCT07260357
- Testing
- ProRoot MTA Pulpotomy, NeoPUTTY MTA Pulpotomy, TheraCal PT Pulpotomy
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Necmettin Erbakan University
Mycoses
An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections
Invasive fungal infections are often life-threatening in persons with immunocompromise. Persons with prolonged neutropenia secondary to cytotoxic chemotherapies are at high risk for these infections.
- Trial name
- NCT00001757
- Testing
- Voriconazole
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ovarian Carcinoma
Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin
The main purpose of this study is to determine the safety and tolerability of giving both paclitaxel and carboplatin in the abdominal cavity by looking at what effects (good and bad) this route of administration has on patients…
- Trial name
- NCT00181701
- Testing
- Paclitaxel, Carboplatin
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
Type 2 Diabetes Mellitus, Hypertension (Without Type 2 Diabetes Mellitus)
Empowering Primary Care Providers and Patients to Improve Chronic Disease Outcomes: The EMPOWER Participatory Action Research (EMPOWER - PAR)
BACKGROUND Chronic disease management (CDM) presents enormous challenges to the primary care workforce due to the rising epidemic of cardiovascular risk factors.
- Trial name
- NCT01545401
- Testing
- EMPOWER-PAR Intervention
- Where
- Malaysia
- Volunteers
- 1,545 people
- Sponsor
- Ministry of Health, Malaysia
Obstructive Sleep Apnea
The Effect of Continuous Positive Airway Therapy on the Blood Pressure in Sleepy vs Non-sleepy Patients With Obstructive Sleep Apnea
Obstructive sleep apnoea (OSA) is one of the most common noncommunicable types of disease, it affects about 1 billion people across the world.
- Trial name
- ANDANTE-REDS (NCT07497412)
- Testing
- Primary airway therapy (e.g., CPAP), Control arm
- Where
- United Kingdom
- Volunteers
- 10,000 people
- Sponsor
- King's College London
Deprescriptions, Antidepressive Agents
Patient-centred Deprescribing of Psychotropic, Sedative and Anticholinergic Medication in Elderly Patients With Polypharmacy
The PARTNER study is a multicentre, two-arm, pragmatic cluster-randomised trial evaluating the impact of a focused and patient-centred cooperation between general practitioners (GPs) and community pharmacists (PARTNER…
- Conditions
- Deprescriptions, Antidepressive Agents, Antipsychotic Agents, Analgesics, Opioid
- Trial name
- PARTNER (NCT05842928)
- Testing
- PARTNER intervention, Control intervention
- Where
- 3 sites in Germany
- Volunteers
- 352 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Cytomegalovirus Infections, Maternal Primary Cytomegalovirus Infection
Evaluation of Software for Interpreting Virological Results Indicated for the Diagnosis of Cytomegalovirus (CMV) Infection During Pregnancy and Intended for Health Professionals
Congenital cytomegalovirus (CMV) infection is the most common congenital infection with a birth prevalence of 0.4% in Europe. It is the leading non-genetic cause of sensorineural hearing loss and a major cause of…
- Trial name
- MyCMV (NCT06694428)
- Testing
- Reinterpretation of CMV serology results using the MyCMV tool on the basis of the serology results performed
- Where
- 3 sites in France
- Volunteers
- 491 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
- Conditions
- Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT03740529
- Testing
- Pirtobrutinib, Venetoclax, Rituximab
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 803 people
- Sponsor
- Loxo Oncology, Inc.
Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
This phase I/II trial studies the side effects and best dose of olaparib and entinostat and to see how well they work in treating patients with ovarian, primary peritoneal, or fallopian tube cancers that have come back or do not…
- Conditions
- Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
- Trial name
- NCT03924245
- Testing
- Entinostat, Olaparib
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Glaucoma
Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.
Evaluate the safety and effectiveness of iSTAR Medical's MINIject™ implant for lowering intraocular pressure (IOP) in subjects with primary open-angle glaucoma.
- Trial name
- STAR-V (NCT05024695)
- Testing
- MINIject™ Implant
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 975 people
- Sponsor
- iSTAR Medical
Primary Breast Cancer
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer
The primary objective of this trial is to compare the rate of pathologically complete remissions achieved using a preoperative dose-intensified 8 week therapy consisting of adriamycin and docetaxel with a preoperative sequential…
- Trial name
- NCT00793377
- Testing
- Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid
- Where
- Germany
- Volunteers
- 913 people
- Sponsor
- GBG Forschungs GmbH
Malignant Melanoma
4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy
Phase Ib/II open-label, multi-center study with a priming cycle of 4SC-202 to evaluate the safety, tolerability and preliminary efficacy of combination treatment with 4SC-202 and Pembrolizumab.
- Trial name
- SENSITIZE (NCT03278665)
- Testing
- 4SC-202 in combination with Pembrolizumab
- Where
- 7 sites in Germany, Italy
- Volunteers
- 40 people
- Sponsor
- 4SC AG
Diffuse Midline Glioma (DMG), Glioblastoma
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other…
- Conditions
- Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma, Recurrent Malignant Central Nervous System Neoplasm
- Trial name
- PNOC023 (NCT04732065)
- Testing
- ONC206, Standard of Care Radiation Therapy, Optional Proton (1H) MR spectroscopy (MRS)
- Where
- 7 sites in United States, Netherlands and 1 more
- Volunteers
- 208 people
- Sponsor
- Sabine Mueller, MD, PhD
Primary Mediastinal (Thymic) Large B-cell Lymphoma, Children
Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma
Addition of nivolumab (immune checkpoint inhibitor) to standard chemotherapy (DA-EPOCH-R) may improve outcome in children with primary mediastinal large B-cell lymphoma
- Conditions
- Primary Mediastinal (Thymic) Large B-cell Lymphoma, Children, Nivolumab
- Trial name
- NCT06871007
- Testing
- Nivolumab
- Where
- 2 sites in Russia
- Volunteers
- 22 people
- Sponsor
- St. Petersburg State Pavlov Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.